No chloroquine/hydroxychloroquine prevention or treatment of COVID-19 is recommended, and look at the 10 studies summarized in the Annals of Internal Medicine!

The preliminary results of in vitro and clinical studies on the prevention or treatment of COVID-19 in the case of chloroquine/hydroxychloroquine alone or a combination of azithromycin have received widespread attentionRecently, the Annals of Internal Medicine published an article from the American Physicians Association (ACP),on the issue of "whether clinicians can use chloroquine/hydroxychloroquine monopills or combined azithromycin to prevent or treat COVID-19" and gave a "NO" recommendationoriginal link:practice pointsthe efficacy ofchloroquine/hydroxychloroquine monodrug or combination amycin to prevent or treat COVID-19 is unclear, and further clinical trials are needed to answer these questionsThese drugs have clear side effects in the treatment of other diseasesAt present, there is little evidence of the efficacy and harm of these drugs used in COVID-19, and the results are contradictory and the quality of the study is not high, which increases the uncertainty of the resultsBased on the available evidence, the ACP has developed the following clinical practice points, which will be updated as new evidence emerges1Due to known side effects and no evidence to support the benefits of the general population, do not use chloroquine/hydroxychloroquine or acombination azithromycin alone topreventCOVID-19;2Because of known side effects and no evidence to support the benefits of COVID-19 patients, do not use chloroquine/hydroxychloroquine or combined azithromycin alone totreatmentCOVID-19;3Due to known side effects and the lack of evidence of benefits for patients with COVID-19, cliniciansa joint decision to make a jointdecision with the knowledge of patients (and family members) to consider using chlorpyrifos/hydroxypicinolinin alone in clinical trialstableCan clinicians use chloroquine/hydroxychloroquine or combined azithromycin to prevent or treat COVID-19?: Due to known side effects and unclear evidence of benefits for patients with COVID-19, clinicians, with the knowledge of patients (and their families), decide to consider treating COVID-19 patients with chloroquine/hydroxychloroquine or combined amychimin in clinical trials aloneevidence take stockof thechart of the
theof theof the of the of the evidence gap in the the efficacy and safety of the chlorpyrifos or combination of amythromycin to prevent or treat Covid-19 (no evidence ) The efficacy and safety of monodrug or combined amycin prevention Covid-19 (no evidence) hydroxychloroquine monodrug or combined amycin treatment the efficacy and safety of covid-19 patients with different severity (insufficient evidence) of of important clinical outcomes, including survival rate, respiratory failure, mechanical ventilation time, use of ECMO (no evidence) except for the use of hydroxychloroquine or combined amycine alone The use and scope of interventions in parallel treatment trials is difficult to determine in non-COVID-19 patients, the known hazards of chloroquine include( but are not limited): cardiovascular disease (cardiomyopathy, electrocardiogram changes), blood system diseases (regenerative anemia, thropoonism), neurological disorders (epilepsy, psychosis, conoric diseases), and macular macular degeneration in non-COVID-19 patients, the known hazards of hydroxychloroquine include (but are not limited): cardiovascular disease (cardiomyopathy, heart failure, ventricular arrhythmia, cutting-edge torsional ventricular velocity), endocrine (hypoglycemia), blood system disease (regenerative anemia, platelet reduction), nervous system (epilepsy, psychosis, concular disease), eye macular degeneration patients (and/or family members) should be informed of the potential harm severity of chloroquine and hydroxychloroquine and insufficient evidence of benefits to patients with COVID-19 evidence reviewed by the indicates that hydroxychloroquine is usually taken for 5-10 days and does not exceed 600 mg per day the benefits of treating other diseases such as rheumatic diseases are clear and are currently in short supply in the United States overuse of antibiotics, such as azithromycin, is an important factor in the of antibiotic resistance and poses a threat to public health Source: